Management

Greg van Wyk

Dr Greg van Wyk – Chief Executive Officer & Chief Medical Officer

Greg graduated as a medical doctor, from the University of the Witwatersrand, in 2001 and worked clinically, in hospitals and in GP practice, for 5 years prior to moving into pharmaceutical medicine. Prior to joining Noxopharm, he enjoyed an 11-year career with Eli Lilly during which he led large, diverse medical teams across Australasia and North-western Europe and worked across a range of therapeutic areas, on medicines in all stages of the product Lifecyle.

In both clinical and commercial contexts, Greg is a strategic thinker who is focused on achieving valued outcomes for the multitude of stakeholders engaged with the pharmaceutical industry. He enjoys research design and analysis and he enjoys continuous learning.

Greg has postgraduate degrees in management and economics and is passionate about the healthcare economy and the role of technology in extending and enhancing people's lives. Greg is also a non-executive director of ADHD Australia, a not for profit organisation aiming to make Australia a better place for people affected by ADHD.


Greg van Wyk

Dr Gisela Mautner – Global Medical Director

MD-PhD (TU&LMU Munich), MPH (Harvard), MBA (Kellogg&WHU), FACPE

Gisela is a medical doctor with over twenty years of experience in the pharma/biotech and medical devices industry gained in Europe, USA, and Australia. In her early career she was a research scientist at the National Institutes of Health (NIH) in Bethesda, USA. Since then, she has focussed on bringing new drugs and therapies to market that improve people's lives through her work in senior roles in Medical Affairs. She is highly attuned to decisions requiring a balance between patient care and commercial interests.

Having lived and worked in many countries, Gisela has gained cultural sensitivities and knowledge that will aid Noxopharm on its global journey. She is fluent in English and German and has conversational skills in Japanese and French.

Gisela understands the growing importance and changing role of Medical Affairs within the pharmaceutical industry. She is currently the VP at APPA (Australian Pharmaceutical medical and scientific Professionals Association) and is a previous treasurer of that association.


John Wilkinson

Dr John Wilkinson - Chief Scientific Officer

John brings over 30 years of experience from both pharmaceutical and research settings in Australia and the United Kingdom, with a focus on the development of small molecules to target viruses and cancer.  John graduated from the University of Portsmouth (BSc Hons) in 1988 and has a PhD in HIV-1 Immunovirology from the University of NSW.  His research interests include Drug Development, Virology, Oncology and Immunology, translating novel laboratory findings into human clinical trials that have previously resulted in numerous peer-reviewed publications.  Prior to joining Noxopharm, John was the Chief Scientific Officer at Biotron Limited, where he was responsible for the oversight of Biotron's antiviral programs and instrumental in the HIV-1 clinical programs.  At Noxopharm, John will manage the scientific, research and technological operations of the company, help set company research and scientific priorities that align with the company's mission and vision.


John Wilkinson

Mark Waring - Senior Vice President US Operations

BSc (Hons), PMP, ASQ C.PGMP

Mark is an executive level project manager/researcher/consultant with a proven track record of designing and effecting positive change in international life science companies. Mark graduated from the University of Sydney in Science (Hons) majoring in Pharmacology and Biochemistry in 1986. He also holds certifications as a Project Management Professional (PMP) from PMI and from the American Society of Quality in Pharmaceutical GMP. He has over 30 yrs experience in Research and Development of Pharmaceutical products and Medical Devices. His early career was spent at the University of Sydney and Royal Prince Alfred Hospital (RPAH) Liver Transplant Unit where he lead a team that developed the first Australian Bio-artificial Liver, trialed in humans with liver failure. As part of his work there he also worked with Dr Kelly to describe many new biologically active isoflavones derived from dietary sources.

He joined Novogen Ltd in 1995 and became an early employee of their US subsidiary in 1998, when he moved there with his wife and family to head Clinical Research and Technical affairs in North America. Mark has held roles of increasing responsibility since, including as a project leader for Deloitte Consulting and Quintiles IMS, advising both large and small clients in medical and clinical research, product approval and launch, professional relationship management, safety surveillance, selection and management of strategic partners and GxP compliant systems.


Ron Sinani

Ron Sinani – Director, Regulatory Affairs

Ron Sinani practised as an oncology pharmacist prior to joining the pharmaceutical industry in 1992. Although his primary focus has been regulatory affairs, he has held roles involving medical affairs, pharmacovigilance, clinical research, quality assurance and health economics. Ron worked for a number of multinationals, including Sandoz (now Novartis), Abbott and Lundbeck before joining Pharmaxis in 2004 to establish its regulatory affairs capabilities and achieving marketing approval of its first product, Aridol® (in vivo diagnostic for asthma) in Australia and a number of global markets. He was also the regulatory lead for the company’s second product, Bronchitol® for the treatment of the orphan disease, cystic fibrosis. These global projects have provided Ron direct experience with overseas regulatory agencies in the US, Canada, Europe and Asia; as well as Australia. More recently, he was a regulatory strategist at Shire Pharmaceuticals where he gained insight into assessment of licensing opportunities and intellectual property protection. Ron has also consulted for the industry, first for Covance and then his own consultancy before joining Noxopharm in 2017.


Lara Babich

Dr Lara Babich - Director, Manufacturing

Born and raised in Trieste (Italy), Lara studied at the University of Padua (Italy), where she received a BSc in Biotechnology and a MSc in Industrial Biotechnology.
She then moved to the Netherlands, where she completed in 2013 a PhD in (bio)Chemistry at the University of Amsterdam working on engineered enzymes to perform chemical processes for the synthesis of pharmaceutical scaffolds.

In 2013, Lara joined Janssen Infectious Diseases and Vaccines (a Johnson&Johnson Company) in Leiden, the Netherlands, as Drug Product Formulation Development scientist working on several  investigational vaccines against infectious diseases like Ebola, HIV, RSV, Polio, etc...  In this role at the interface between R&D and GMP manufacturing, she worked on the development and implementation of liquid sterile formulations for injectable vaccines (biologics). Being part of the Chemistry, Manufacturing and Control (CMC team), Lara worked in several cross-functional and cross-site teams coordinating the path towards the start of each clinical phase.

After relocating to Australia, Lara joined Noxopharm in January 2018 as Director of Manufacturing, where she coordinates NOX66 process development, manufacturing, quality control and testing.


Frederic Delebecque

Dr Frederic Delebecque – Director, Pre-Clinical Oncology

Frederic has a PhD in Virology from the University Pierre and Marie Curie in Paris, France, achieved at the Pasteur Institute. Following his PhD, he performed his postdoctoral training at the Pasteur Institute and at the prestigious University of California, Berkeley. He also has a degree in chemical engineering from the National Engineer School of Chemistry in Montpellier, France. In addition to his academic training, Frederic has extensive experience in Research and Development and Quality Assurance at leading pharmaceutical and biotech companies, including pre-clinical, clinical and medical research spanning several disease areas.

In 2009, Frederic joined Novartis Pharma AG in Basel, Switzerland as a Principal Scientist in the Laboratory of Cell line and Adventitious agents Analytics. He was involved in multiple cross-functional projects within Regulatory Chemistry, Manufacturing and Controls and oversaw the adventitious agents testing of production cell banks for biologicals generating regulatory documents for submission to health authorities (FDA, Swissmedic and EMA).

In 2011, Frederic moved to Australia and joined Calimmune, a clinical-stage multinational biotech company, as a Senior Scientist to supervise their pre-clinical work. After approval to conduct a Phase I/II clinical trial in the USA to test a unique stem-cell based gene therapy against HIV, Frederic moved to a Quality Assurance Director position in 2013. In this role, he was responsible for all Quality Assurance, including the development, implementation and maintenance of the Quality Management System globally across Australia and the USA.

Frederic joined Noxopharm in 2017 as the Director of Pre-clinical Oncology.


Phillip Coghlan

Dr Phillip Coghlan - Director, Pharmaceutical Chemistry

Dr Phillip Coghlan joins Noxopharm having spent the past 16 years in industry regulation at the Australian Pesticides and Veterinary Medicines Authority (APVMA) where he was a Chemistry Evaluator, the Principal Pharmaceutical Chemist and most recently Director of Scientific Standards and Data Guidelines. Dr Coghlan also spent time at the Therapeutic Goods Administration (TGA) as an evaluator of prescription medicines. Dr Coghlan has a strong scientific background in biochemistry (BAppSc, Swinburne), organic chemistry (PhD, ANU) and early stage drug development (CSIRO) which he will use to help direct manufacture of Active Pharmaceutical Ingredients and Finished Drug Products. Dr Coghlan brings a wealth of knowledge and understanding of pharmaceutical chemistry and manufacture assessment and regulation to the role.